Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II open-label study of HRS-6208 combinations in advanced unresectable or metastatic breast cancer
CTR20260338Phase 2Active
- Sponsor
- Shandong Sende
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HRS-6208 in breast cancer, sponsored by Shandong Sende. Started Mar 2026; status: active.
02
Drugs
HRS-6208
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20260338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260338.